{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T23:06:33Z","timestamp":1788822393328,"version":"build-2803163510"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2023,1,10]],"date-time":"2023-01-10T00:00:00Z","timestamp":1673308800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Takeda Pharmaceuticals Taiwan, Ltd."}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,11,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>This nationwide prospective registry study investigated the real-world effectiveness, safety, and persistence of vedolizumab (VDZ) in inflammatory bowel disease (IBD) patients in Taiwan. Disease relapse rates after VDZ discontinuation due to reimbursement restriction were assessed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Data were collected prospectively (January 2018 to May 2020) from the Taiwan Society of IBD registry.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Overall, 274 patients (147 ulcerative colitis [UC] patients, 127 Crohn\u2019s disease [CD] patients) were included. Among them, 70.7% with UC and 50.4% with CD were biologic-na\u00efve. At 1 year, 76.0%, 58.0%, 35.0%, and 62.2% of UC patients and 57.1%, 71.4%, 33.3%, and 30.0% of CD patients achieved clinical response, clinical remission, steroid-free remission, and mucosal healing, respectively. All patients underwent hepatitis B and tuberculosis screening before initiating biologics, and prophylaxis was recommended when necessary. One hepatitis B carrier, without antiviral prophylaxis due to economic barriers, had hepatitis B reactivation during steroid tapering and increasing azathioprine dosage, which was controlled with an antiviral agent. No tuberculosis reactivation was noted. At 12 months, non\u2013reimbursement-related treatment persistence rates were 94.0% and 82.5% in UC and CD patients, respectively. Moreover, 75.3% of IBD patients discontinued VDZ due to mandatory drug holiday. Relapse rates after VDZ discontinuation at 6 and 12 months were 36.7% and 64.3% in CD patients and 42.9% and 52.4% in UC patients, respectively.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>The findings demonstrated VDZ effectiveness in IBD patients in Taiwan, with high treatment persistence rates and favorable safety profiles. A substantial IBD relapse rate was observed in patients who had mandatory drug holiday.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ibd\/izac269","type":"journal-article","created":{"date-parts":[[2023,1,10]],"date-time":"2023-01-10T19:16:39Z","timestamp":1673378199000},"page":"1730-1740","source":"Crossref","is-referenced-by-count":23,"title":["Real-World Evidence of Effectiveness and Safety of Vedolizumab for Inflammatory Bowel Disease in Taiwan: A Prospective Nationwide Registry (VIOLET) Study"],"prefix":"10.1093","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8142-538X","authenticated-orcid":false,"given":"Wei-Chen","family":"Lin","sequence":"first","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Internal Medicine, Mackay Memorial Hospital , Taipei , Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Chen","family":"Tai","sequence":"additional","affiliation":[{"name":"Division of Hepatogastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital , Kaohsiung , Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chung-Hsin","family":"Chang","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Internal Medicine, Taichung Veterans General Hospital , Taichung , Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-Hung","family":"Tu","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, National Taiwan University Hospital, National Taiwan University College of Medicine , Taipei , Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I-Che","family":"Feng","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Chi Mei Medical Center , Tainan , Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Jium","family":"Shieh","sequence":"additional","affiliation":[{"name":"Department of Oncology, National Taiwan University Hospital , Taipei , Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen-Shuan","family":"Chung","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Internal Medicine, Far Eastern Memorial Hospital , New Taipei City , Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsu-Heng","family":"Yen","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Internal Medicine, Changhua Christian Hospital, Changhua , Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jen-Wei","family":"Chou","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Internal Medicine, China Medical University Hospital , Taichung , Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jau-Min","family":"Wong","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, National Taiwan University Hospital, National Taiwan University College of Medicine , Taipei , Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Hwa","family":"Liu","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Internal Medicine, Shin Kong Wu Ho-Su Memorial Hospital , Taipei , Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tien-Yu","family":"Huang","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical Center , Taipei , Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiao-Hsiung","family":"Chuang","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Medical College and Hospital, National Cheng Kung University , Tainan , Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tzung-Jiun","family":"Tsai","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Medicine, Kaohsiung Veterans General Hospital , Kaohsiung , Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng-Fan","family":"Chiang","sequence":"additional","affiliation":[{"name":"Division of Colon and Rectal Surgery, Department of Surgery, Taichung Veterans General Hospital , Taichung , Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chien-Yu","family":"Lu","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University , Kaohsiung , Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Hung","family":"Hsu","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University , Kaohsiung , Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang-Jung","family":"Yu","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University , Kaohsiung , Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Te-Hsin","family":"Chao","sequence":"additional","affiliation":[{"name":"Division of Colon and Rectal Surgery, Department of Surgery, Chiayi and Wangiao Branch, Taichung Veterans General Hospital , Taichung , Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deng-Chyang","family":"Wu","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University , Kaohsiung , Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ai-Sheng","family":"Ho","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Internal Medicine, Cheng Hsin General Hospital , Taipei , Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hung-Hsin","family":"Lin","sequence":"additional","affiliation":[{"name":"Division of Colon and Rectal Surgery, Department of Surgery, Taipei Veterans General Hospital , Taipei , Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Lung","family":"Feng","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, China Medical University Hsinchu Hospital , Hsinchu , Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keng-Liang","family":"Wu","sequence":"additional","affiliation":[{"name":"Division of Hepato-Gastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung , Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Wun","family":"Wong","sequence":"additional","affiliation":[{"name":"Department of Medicine, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation and Tzu Chi University , Hualien , Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chien-Chih","family":"Tung","sequence":"additional","affiliation":[{"name":"Department of Integrated Diagnostics and Therapeutics, National Taiwan University Hospital , Taipei , Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Chi","family":"Lin","sequence":"additional","affiliation":[{"name":"Division of Colon and Rectal Surgery, Department of Surgery, Taipei Veterans General Hospital , Taipei , Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-Chang","family":"Chen","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Internal Medicine, Taichung Veterans General Hospital , Taichung , Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huang-Ming","family":"Hu","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University , Kaohsiung , Taiwan"},{"name":"Department of Internal Medicine, Kaohsiung Municipal Ta-Tung Hospital , Kaohsiung , Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lung-Sheng","family":"Lu","sequence":"additional","affiliation":[{"name":"Division of Hepato-Gastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine , Kaohsiung , Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huann-Sheng","family":"Wang","sequence":"additional","affiliation":[{"name":"Division of Colorectal Surgery, Department of Surgery, Taipei Veterans General Hospital, National Yang Ming Chiao Tung University , Taipei , Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I-Chen","family":"Wu","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University , Kaohsiung , Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsin-Yu","family":"Kuo","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University , Tainan , Taiwan"},{"name":"Institute of Clinical Medicine, College of Medicine, National Cheng Kung University , Tainan , Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Feng","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, National Taiwan University Hospital , Taipei , Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsiang","family":"Yao Shih","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University , Kaohsiung , Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yen-Hsuan","family":"Ni","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, College of Medicine, National Taiwan University , Taipei , Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu-Lun","family":"Tang","sequence":"additional","affiliation":[{"name":"Takeda Pharmaceuticals Taiwan, Ltd. , Taipei , Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng-Hsu","family":"Chen","sequence":"additional","affiliation":[{"name":"Takeda Pharmaceuticals Taiwan, Ltd. , Taipei , Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5017-5840","authenticated-orcid":false,"given":"Shu-Chen","family":"Wei","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, National Taiwan University Hospital, National Taiwan University College of Medicine , Taipei , Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,1,10]]},"reference":[{"issue":"1","key":"2024030712034896400_CIT0001","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1093\/ecco-jcc\/jjab178","article-title":"ECCO guidelines on therapeutics in ulcerative colitis: medical treatment","volume":"16","author":"Raine","year":"2022","journal-title":"J Crohns Colitis"},{"issue":"1","key":"2024030712034896400_CIT0002","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/ecco-jcc\/jjz180","article-title":"ECCO guidelines on therapeutics in Crohn\u2019s disease: medical treatment","volume":"14","author":"Torres","year":"2020","journal-title":"J Crohns Colitis"},{"issue":"1","key":"2024030712034896400_CIT0003","doi-asserted-by":"crossref","first-page":"e135","DOI":"10.1038\/ctg.2015.63","article-title":"Loss of response to anti-TNFs: definition, epidemiology, and management","volume":"7","author":"Roda","year":"2016","journal-title":"Clin Transl Gastroenterol"},{"issue":"17","key":"2024030712034896400_CIT0004","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1001\/jama.2017.16071","article-title":"Association between use of thiopurines or tumor necrosis factor antagonists alone or in combination and risk of lymphoma in patients with inflammatory bowel disease","volume":"318","author":"Lemaitre","year":"2017","journal-title":"JAMA."},{"issue":"8","key":"2024030712034896400_CIT0005","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/j.dld.2020.05.031","article-title":"Incidence of suboptimal response to tumor necrosis factor antagonist therapy in inflammatory bowel disease in newly industrialised countries: the EXPLORE study","volume":"52","author":"Yamamoto-Furusho","year":"2020","journal-title":"Dig Liver Dis."},{"issue":"12","key":"2024030712034896400_CIT0006","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1093\/ecco-jcc\/jjw092","article-title":"An overview of the mechanism of action of the monoclonal antibody vedolizumab","volume":"10","author":"Wyant","year":"2016","journal-title":"J Crohns Colitis"},{"issue":"5","key":"2024030712034896400_CIT0007","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1093\/ibd\/izy313","article-title":"A practical guide to the safety and monitoring of new IBD Therapies","volume":"25","author":"Click","year":"2019","journal-title":"Inflamm Bowel Dis."},{"issue":"4","key":"2024030712034896400_CIT0008","first-page":"400","article-title":"Long-term efficacy of vedolizumab for ulcerative colitis","volume":"11","author":"Loftus","year":"2017","journal-title":"J Crohns Colitis"},{"issue":"4","key":"2024030712034896400_CIT0009","first-page":"412","article-title":"Long-term efficacy of vedolizumab for Crohn\u2019s disease","volume":"11","author":"Vermeire","year":"2017","journal-title":"J Crohns Colitis"},{"issue":"1","key":"2024030712034896400_CIT0010","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/apt.15538","article-title":"Vedolizumab use is not associated with increased malignancy incidence: GEMINI LTS study results and post-marketing data","volume":"51","author":"Card","year":"2020","journal-title":"Aliment Pharmacol Ther."},{"issue":"1","key":"2024030712034896400_CIT0011","doi-asserted-by":"crossref","first-page":"83","DOI":"10.5217\/ir.2019.09160","article-title":"Efficacy and safety of vedolizumab in Crohn\u2019s disease in patients from Asian countries in the GEMINI 2 study","volume":"19","author":"Banerjee","year":"2021","journal-title":"Intest Res"},{"issue":"11","key":"2024030712034896400_CIT0012","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1007\/s40265-014-0253-1","article-title":"Vedolizumab: first global approval","volume":"74","author":"Poole","year":"2014","journal-title":"Drugs."},{"issue":"6","key":"2024030712034896400_CIT0013","doi-asserted-by":"crossref","first-page":"685","DOI":"10.5009\/gnl19209","article-title":"Biologics for the management of inflammatory bowel disease: a review in tuberculosis-endemic countries","volume":"14","author":"Banerjee","year":"2020","journal-title":"Gut Liver"},{"issue":"4","key":"2024030712034896400_CIT0014","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1111\/apt.15921","article-title":"Comparative safety and effectiveness of vedolizumab to tumour necrosis factor antagonist therapy for Crohn\u2019s disease","volume":"52","author":"Bohm","year":"2020","journal-title":"Aliment Pharmacol Ther."},{"issue":"1","key":"2024030712034896400_CIT0015","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.cgh.2020.10.003","article-title":"Comparative safety and effectiveness of vedolizumab to tumor necrosis factor antagonist therapy for ulcerative colitis","volume":"20","author":"Lukin","year":"2022","journal-title":"Clin Gastroenterol Hepatol."},{"issue":"1","key":"2024030712034896400_CIT0016","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/apt.15294","article-title":"Three-year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multi-centre cohort study","volume":"50","author":"Amiot","year":"2019","journal-title":"Aliment Pharmacol Ther."},{"issue":"6","key":"2024030712034896400_CIT0017","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1111\/apt.14919","article-title":"Real-world clinical, endoscopic and radiographic efficacy of vedolizumab for the treatment of inflammatory bowel disease","volume":"48","author":"Kotze","year":"2018","journal-title":"Aliment Pharmacol Ther."},{"issue":"3","key":"2024030712034896400_CIT0018","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1097\/MIB.0000000000001039","article-title":"Efficacy and safety of vedolizumab for induction of remission in inflammatory bowel disease-the israeli real-world experience","volume":"23","author":"Kopylov","year":"2017","journal-title":"Inflamm Bowel Dis."},{"issue":"12","key":"2024030712034896400_CIT0019","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1093\/ibd\/izaa361","article-title":"Clinical outcomes and response predictors of vedolizumab induction treatment for Korean patients with inflammatory bowel diseases who failed anti-TNF therapy: a KASID prospective multicenter cohort study","volume":"27","author":"Kim","year":"2021","journal-title":"Inflamm Bowel Dis."},{"key":"2024030712034896400_CIT0020","doi-asserted-by":"crossref","first-page":"17562848211024717562848211024769","DOI":"10.1177\/17562848211024769","article-title":"The real-world outcomes of vedolizumab in patients with ulcerative colitis in Korea: a multicenter retrospective study","volume":"14","author":"Ye","year":"2021","journal-title":"Therap Adv Gastroenterol"},{"key":"2024030712034896400_CIT0021","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1002\/aid2.13188","article-title":"Real-world efficacy and safety of vedolizumab among patients with inflammatory bowel disease: a single tertiary medical center experience in Central Taiwan","volume":"8","author":"Chiu","year":"2020","journal-title":"Adv Dig Med"},{"issue":"9","key":"2024030712034896400_CIT0022","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1016\/j.jfma.2021.11.012","article-title":"The effectiveness and safety of vedolizumab induction for moderate to severe ulcerative colitis for Asia patient: a real practice observational study","volume":"121","author":"Kuo","year":"2022","journal-title":"J Formos Med Assoc."},{"issue":"7","key":"2024030712034896400_CIT0023","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/j.jfma.2018.07.005","article-title":"Inflammatory bowel disease and its treatment in 2018: Global and Taiwanese status updates","volume":"118","author":"Su","year":"2019","journal-title":"J Formos Med Assoc."},{"issue":"3","key":"2024030712034896400_CIT0024","doi-asserted-by":"crossref","first-page":"266","DOI":"10.5217\/ir.2017.15.3.266","article-title":"Management of ulcerative colitis in Taiwan: consensus guideline of the Taiwan Society of Inflammatory Bowel Disease","volume":"15","author":"Wei","year":"2017","journal-title":"Intest Res"},{"issue":"1","key":"2024030712034896400_CIT0025","doi-asserted-by":"crossref","first-page":"54","DOI":"10.5217\/ir.2018.00096","article-title":"Epidemiological trend in inflammatory bowel disease in Taiwan from 2001 to 2015: a nationwide population-based study","volume":"17","author":"Yen","year":"2019","journal-title":"Intest Res"},{"issue":"9","key":"2024030712034896400_CIT0026","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1093\/ibd\/izz276","article-title":"Short disease duration is associated with increased risk of treatment failure in biologic-treated patients with ulcerative colitis","volume":"26","author":"Nguyen","year":"2020","journal-title":"Inflamm Bowel Dis."},{"issue":"12","key":"2024030712034896400_CIT0027","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1016\/j.cgh.2018.12.040","article-title":"Shorter disease duration is associated with higher rates of response to vedolizumab in patients with Crohn\u2019s disease but not ulcerative colitis","volume":"17","author":"Faleck","year":"2019","journal-title":"Clin Gastroenterol Hepatol."},{"issue":"8","key":"2024030712034896400_CIT0028","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1215734","article-title":"Vedolizumab as induction and maintenance therapy for ulcerative colitis","volume":"369","author":"Feagan","year":"2013","journal-title":"N Engl J Med."},{"issue":"8","key":"2024030712034896400_CIT0029","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1215739","article-title":"Vedolizumab as Induction and Maintenance Therapy for Crohn\u2019s Disease","volume":"369","author":"Sandborn","year":"2013","journal-title":"N Engl J Med."},{"issue":"5","key":"2024030712034896400_CIT0030","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1136\/gutjnl-2015-311079","article-title":"The safety of vedolizumab for ulcerative colitis and Crohn\u2019s disease","volume":"66","author":"Colombel","year":"2017","journal-title":"Gut."},{"issue":"7","key":"2024030712034896400_CIT0031","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1038\/ajg.2012.89","article-title":"A pooled analysis of infections, malignancy, and mortality in infliximab- and immunomodulator-treated adult patients with inflammatory bowel disease","volume":"107","author":"Lichtenstein","year":"2012","journal-title":"Am J Gastroenterol."},{"issue":"4","key":"2024030712034896400_CIT0032","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1136\/annrheumdis-2011-201244","article-title":"Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn\u2019s disease","volume":"72","author":"Burmester","year":"2013","journal-title":"Ann Rheum Dis."},{"issue":"10","key":"2024030712034896400_CIT0033","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1093\/ecco-jcc\/jjab058","article-title":"Vedolizumab and anti-tumour necrosis factor \u03b1 real-world outcomes in biologic-na\u00efve inflammatory bowel disease patients: results from the EVOLVE study","volume":"15","author":"Bressler","year":"2021","journal-title":"J Crohns Colitis"},{"issue":"9","key":"2024030712034896400_CIT0034","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1007\/s00535-018-1480-0","article-title":"Systematic review with meta-analysis: real-world effectiveness and safety of vedolizumab in patients with inflammatory bowel disease","volume":"53","author":"Schreiber","year":"2018","journal-title":"J Gastroenterol."},{"issue":"7","key":"2024030712034896400_CIT0035","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1097\/MEG.0000000000001403","article-title":"Inflammatory bowel disease and mycobacteria: how much can we trust isoniazid prophylaxis during antitumor necrosis factor therapy","volume":"31","author":"Akyuz","year":"2019","journal-title":"Eur J Gastroenterol Hepatol."},{"issue":"1","key":"2024030712034896400_CIT0036","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1053\/j.gastro.2014.10.038","article-title":"American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy","volume":"148","author":"Perrillo","year":"2015","journal-title":"Gastroenterology."},{"issue":"4","key":"2024030712034896400_CIT0037","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.cgh.2020.06.071","article-title":"No benefit of concomitant immunomodulator therapy on efficacy of biologics that are not tumor necrosis factor antagonists in patients with inflammatory bowel diseases: a meta-analysis","volume":"19","author":"Yzet","year":"2021","journal-title":"Clin Gastroenterol Hepatol."},{"issue":"1","key":"2024030712034896400_CIT0038","first-page":"15","article-title":"Effectiveness and persistence of Vedolizumab in patients with inflammatory bowel disease: results from the Belgian REal-LIfe study with VEdolizumab (Be-RELIVE)","volume":"83","author":"Reenaers","year":"2020","journal-title":"Acta Gastroenterol Belg."},{"issue":"7","key":"2024030712034896400_CIT0039","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1093\/ecco-jcc\/jjaa005","article-title":"Maintenance of remission among patients with inflammatory bowel disease after vedolizumab discontinuation: a multicentre cohort study","volume":"14","author":"Martin","year":"2020","journal-title":"J Crohns Colitis"},{"issue":"2","key":"2024030712034896400_CIT0040","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1159\/000503859","article-title":"Persistence with biologic treatment in patients with inflammatory bowel disease: a German claims data analysis","volume":"102","author":"Mevius","year":"2021","journal-title":"Digestion."}],"container-title":["Inflammatory Bowel Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ibdjournal\/advance-article-pdf\/doi\/10.1093\/ibd\/izac269\/48601111\/izac269.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/29\/11\/1730\/56890692\/izac269.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/29\/11\/1730\/56890692\/izac269.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,7]],"date-time":"2024-03-07T12:04:54Z","timestamp":1709813094000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article\/29\/11\/1730\/6982880"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,10]]},"references-count":40,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2023,1,10]]},"published-print":{"date-parts":[[2023,11,2]]}},"URL":"https:\/\/doi.org\/10.1093\/ibd\/izac269","relation":{},"ISSN":["1078-0998","1536-4844"],"issn-type":[{"value":"1078-0998","type":"print"},{"value":"1536-4844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,11,1]]},"published":{"date-parts":[[2023,1,10]]}}}